FDA Approves IRBESARTAN AND HYDROCHLOROTHIAZIDE — Teva Pharmaceuticals USA, Inc.

# FDA Approves Teva's Generic Irbesartan and Hydrochlorothiazide Combination Teva Pharmaceuticals USA, Inc. received FDA approval for a generic version of the irbesartan and hydrochlorothiazide combination tablet, an oral antihypertensive medication, expanding the competitive landscape in the blood pressure management market. The approval enables Teva to capture market share from branded versions and is expected to increase patient access to this combination therapy at a lower cost.